CNTA

CentessaB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$42.00

+5.4% vs current

Most likely

Base case

55%

Probability

Target price

$39.80

-0.1% vs current

B-

Bear case

20%

Probability

Target price

$30.00

-24.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-15

AI commentary

Sentiment remains cautiously constructive but still deal-centric. The main primary-source update for this T+3 run was the May 5, 2026 10-Q, which confirmed the transaction framework and showed enough liquidity to keep financing risk from becoming the immediate issue before close. I did not find a stronger delayed post-earnings analyst revision signal from trustworthy checked sources, so the lack of new negative reaction should not be over-read as fresh positive evidence. The stock's May 14, 2026 anchor at $39.60 appears to reflect merger spread plus some CVR value, not a new standalone biotech rerating.

RankAlpha Sentiment Codex - 2026-05-15

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-05catalystPost-earnings 10-Q reinforced deal-close runway rather than a new standalone reratingMedium impact

Centessa's May 5, 2026 10-Q showed $533.7 million of cash, cash equivalents and investments as of March 31, 2026, alongside a $79.2 million net loss and $72.2 million of operating cash burn for the quarter; that lowers immediate financing pressure while the Lilly transaction is pending, but it did not create a new independent operating thesis [#10-Q-2026-05-05].

2026-06-12eventJune 12 shareholder and scheme meetings are the next concrete merger checkpointMedium impact

Centessa's April 28, 2026 proxy says the special meetings tied to the Lilly acquisition are expected to be held on June 12, 2026 immediately before the AGM, making that date the next visible de-risking step for the court-sanctioned scheme process [#DEF14A-2026-04-28].

2026-09-30catalystDeal closing and CVR realization remain the two value bucketsMedium impact

The 10-Q reiterates Lilly's consideration of $38.00 cash per share plus a non-transferable CVR worth up to $9.00 per share, with closing expected in Q3 2026 subject to shareholder, court and regulatory approvals; the CVR depends on future U.S. approvals for cleminorexton or ORX142 in idiopathic hypersomnia, any indication, and narcolepsy type 2, so most upside beyond cash remains long-dated and uncertain [#10-Q-2026-05-05] [#8-K-2026-03-31].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-15 • Updated nightlySource: Internal modelMethodology